Takahashi K, et al. - In Japanese patients with polypoidal choroidal vasculopathy over 12 months, authors compared the effectiveness and safety of ranibizumab 0.5 mg with or without verteporfin photodynamic therapy. They noted an agreement of the results from the Japanese cohort with the EVEREST II study. Compared to monotherapy, they noted the efficacy of combination therapy in improving BCVA and achieving a higher rate of complete polyp regression with a lower number of ranibizumab injections. Over 12 months, no new safety signals were reported, and safety events were comparable between both arms.